Table 2 Patient characteristics table separated by cross-validation (kth) fold
From: Predicting progression events in multiple myeloma from routine blood work
kth-fold | k =1 | k = 2 | k = 3 | k = 4 | k = 5 |
|---|---|---|---|---|---|
Patients | 175 | 175 | 175 | 175 | 175 |
Female | 73 | 55 | 79 | 67 | 79 |
Male | 102 | 120 | 96 | 108 | 96 |
Age | 65 ± 11 | 64 ± 10 | 64 ± 10 | 62 ± 10 | 63 ± 11 |
Stem Cell Transplantees | 97 | 108 | 87 | 99 | 103 |
ISS | |||||
1 | 56 | 69 | 53 | 63 | 58 |
2 | 70 | 56 | 61 | 62 | 64 |
3 | 46 | 47 | 59 | 48 | 51 |
Treatment classification | |||||
Bortezomib-based | 39 | 33 | 42 | 33 | 40 |
Carfilzomib-based | 2 | 0 | 2 | 0 | 0 |
IMIDs-based | 11 | 14 | 6 | 8 | 10 |
combined IMIDs/carfilzomib-based | 11 | 11 | 9 | 12 | 8 |
combined bortezomib/IMIDs-based | 107 | 104 | 111 | 112 | 107 |
combined bortezomib/IMIDs/carfilzomib-based | 5 | 12 | 5 | 9 | 9 |
combined bortezomib/carfilzomib-based | 0 | 1 | 0 | 0 | 1 |
combined daratumumab/IMIDs/carfilzomib-based | 0 | 0 | 0 | 1 | 0 |
Total Visits | 3435 | 3269 | 3281 | 3483 | 3307 |
Total Progression Events | 240 | 253 | 197 | 255 | 292 |
Lab value counts | |||||
Hemoglobin | 3056 | 2902 | 2806 | 3112 | 2876 |
Calcium | 2992 | 2847 | 2748 | 3043 | 2799 |
Creatinine | 3017 | 2863 | 2778 | 3066 | 2822 |
LDH | 1999 | 2006 | 1882 | 1913 | 1951 |
Albumin | 2929 | 2784 | 2711 | 3009 | 2756 |
β-2-Microglobulin | 1061 | 1028 | 850 | 791 | 977 |
M-Protein | 2622 | 2585 | 2379 | 2692 | 2447 |
SFL-λ | 2806 | 2605 | 2503 | 2826 | 2630 |
SFL-κ | 2818 | 2612 | 2510 | 2834 | 2625 |
WBC | 3057 | 2904 | 2802 | 3108 | 2877 |
